Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioRestorative Therapies (BRTX) FCF Margin (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed FCF Margin for 15 consecutive years, with 24808.03% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, FCF Margin fell 2405545.0% year-over-year to 24808.03%, compared with a TTM value of 2808.12% through Sep 2025, down 78312.0%, and an annual FY2024 reading of 2071.37%, up 245624.0% over the prior year.
  • FCF Margin was 24808.03% for Q3 2025 at BioRestorative Therapies, down from 888.19% in the prior quarter.
  • Across five years, FCF Margin topped out at 752.57% in Q3 2024 and bottomed at 44818.08% in Q4 2022.
  • Average FCF Margin over 5 years is 9303.84%, with a median of 5380.91% recorded in 2024.
  • The sharpest move saw FCF Margin surged 3622748bps in 2023, then plummeted -2405545bps in 2025.
  • Year by year, FCF Margin stood at 22900.28% in 2021, then tumbled by -96bps to 44818.08% in 2022, then surged by 81bps to 8590.6% in 2023, then soared by 37bps to 5380.91% in 2024, then crashed by -361bps to 24808.03% in 2025.
  • Business Quant data shows FCF Margin for BRTX at 24808.03% in Q3 2025, 888.19% in Q2 2025, and 11260.74% in Q1 2025.